Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Feb 19:15:1294415.
doi: 10.3389/fendo.2024.1294415. eCollection 2024.

Safe long-term therapy of Cushing's syndrome over 37 years with mitotane

Affiliations
Review

Safe long-term therapy of Cushing's syndrome over 37 years with mitotane

Jonas Seibold et al. Front Endocrinol (Lausanne). .

Abstract

While suggested, surgery is not always possible as a first-line treatment of Cushing's Disease (CD). In such cases, patients require medical therapy in order to prevent complications resulting from hypercortisolism. Although there has been a wide expansion in pharmacological options in recent years, mitotane was the agent of choice for treating hypercortisolism decades ago. Due to the introduction of other therapies, long-term experience with mitotane remains limited. Here, we report the case of a woman with CD who was treated with mitotane for 37 years. During the treatment period, biochemical and clinical disease control was achieved and the patient had two uncomplicated pregnancies. Drug-related side effects remained moderate and could be controlled by several dose adjustments. Our case highlights the ability of mitotane to allow an effective control of hypercortisolism and to represent a safe treatment option in special situations where CD requires an alternative therapeutic approach. Furthermore, we provide a literature review of the long-term use of mitotane and reported cases of pregnancy in the context of mitotane therapy.

Keywords: Cushing’s syndrome; adrenostatic drug; long-term treatment; mitotane; pregnancy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. Fleseriu M, Auchus R, Bancos I, Ben-Shlomo A, Bertherat J, Biermasz NR, et al. . Consensus on diagnosis and management of Cushing’s disease: a guideline update. Lancet Diabetes Endocrinol (2021) 9:847–75. doi: 10.1016/S2213-8587(21)00235-7 - DOI - PMC - PubMed
    1. Nieman LK, Biller BM, Findling JW, Murad MH, Newell-Price J, Savage MO, et al. . Treatment of Cushing’s syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab (2015) 100:2807–31. doi: 10.1210/jc.2015-1818 - DOI - PMC - PubMed
    1. Tritos NA. Adrenally directed medical therapies for cushing syndrome. J Clin Endocrinol Metab (2021) 106:16–25. doi: 10.1210/clinem/dgaa778 - DOI - PubMed
    1. Pivonello R, De Leo M, Cozzolino A, Colao A. The treatment of Cushing’s disease. Endocrine Rev (2015) 36:385–486. doi: 10.1210/er.2013-1048 - DOI - PMC - PubMed
    1. Pivonello R, Fleseriu M, Newell-Price J, Bertagna X, Findling J, Shimatsu A, et al. . Efficacy and safety of osilodrostat in patients with Cushing’s disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase. Lancet Diabetes Endocrinol (2020) 8:748–61. doi: 10.1016/S2213-8587(20)30240-0 - DOI - PubMed